Literature DB >> 25691154

Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.

Kasyapa Chitta1, Aneel Paulus, Sharoon Akhtar, Maja Kristin K Blake, Thomas R Caulfield, Anne J Novak, Stephen M Ansell, Pooja Advani, Sikander Ailawadhi, Taimur Sher, Stig Linder, Asher Chanan-Khan.   

Abstract

Deubiquitinase enzymes (DUBs) of the proteasomal 19S regulatory particle are emerging as important therapeutic targets in several malignancies. Here we demonstrate that inhibition of two proteasome-associated DUBs (USP14 and UCHL5) with the small molecule DUB inhibitor b-AP15, results in apoptosis of human Waldenström macroglobulinaemia (WM) cell lines and primary patient-derived WM tumour cells. Importantly, b-AP15 produced proteotoxic stress and apoptosis in WM cells that have acquired resistance to the proteasome inhibitor bortezomib. In silico modelling identified protein residues that were critical for the binding of b-AP15 with USP14 or UCHL5 and proteasome enzyme activity assays confirmed that b-AP15 does not affect the proteolytic capabilities of the 20S proteasome β-subunits. In vitro toxicity from b-AP15 appeared to result from a build-up of ubiquitinated proteins and activation of the endoplasmic reticulum stress response in WM cells, an effect that also disrupted the mitochondria. Focused transcriptome profiling of b-AP15-treated WM cells revealed modulation of several genes regulating cell stress and NF-κB signalling, the latter whose protein translocation and downstream target activation was reduced by b-AP15 in vitro. This is the first report to define the effects and underlying mechanisms associated with inhibition of USP14 and UCHL5 DUB activity in WM tumour cells.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Waldenströms macroglobulinaemia; deubiquitinase enzymes; preclinical; proteasome; transcriptome

Mesh:

Substances:

Year:  2015        PMID: 25691154      PMCID: PMC4846423          DOI: 10.1111/bjh.13304

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  52 in total

1.  A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Authors:  Dharminder Chauhan; Ze Tian; Benjamin Nicholson; K G Suresh Kumar; Bin Zhou; Ruben Carrasco; Jeffrey L McDermott; Craig A Leach; Mariaterresa Fulcinniti; Matthew P Kodrasov; Joseph Weinstock; William D Kingsbury; Teru Hideshima; Parantu K Shah; Stephane Minvielle; Mikael Altun; Benedikt M Kessler; Robert Orlowski; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

Review 2.  Proteasome deubiquitinases as novel targets for cancer therapy.

Authors:  Pádraig D'Arcy; Stig Linder
Journal:  Int J Biochem Cell Biol       Date:  2012-07-20       Impact factor: 5.085

3.  Inhibition of proteasome deubiquitinating activity as a new cancer therapy.

Authors:  Pádraig D'Arcy; Slavica Brnjic; Maria Hägg Olofsson; Mårten Fryknäs; Kristina Lindsten; Michelandrea De Cesare; Paola Perego; Behnam Sadeghi; Moustapha Hassan; Rolf Larsson; Stig Linder
Journal:  Nat Med       Date:  2011-11-06       Impact factor: 53.440

4.  A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.

Authors:  Ze Tian; Padraig D'Arcy; Xin Wang; Arghya Ray; Yu-Tzu Tai; Yiguo Hu; Ruben D Carrasco; Paul Richardson; Stig Linder; Dharminder Chauhan; Kenneth C Anderson
Journal:  Blood       Date:  2013-12-06       Impact factor: 22.113

5.  Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines.

Authors:  Ulrika Rolén; Vera Kobzeva; Natalja Gasparjan; Huib Ovaa; Gösta Winberg; Fjodor Kisseljov; Maria G Masucci
Journal:  Mol Carcinog       Date:  2006-04       Impact factor: 4.784

6.  Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994.

Authors:  F D Groves; L B Travis; S S Devesa; L A Ries; J F Fraumeni
Journal:  Cancer       Date:  1998-03-15       Impact factor: 6.860

7.  Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.

Authors:  Crystina L Kriss; Javier A Pinilla-Ibarz; Adam W Mailloux; John J Powers; Chih-Hang Anthony Tang; Chang Won Kang; Nicola Zanesi; Pearlie K Epling-Burnette; Eduardo M Sotomayor; Carlo M Croce; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  Blood       Date:  2012-06-12       Impact factor: 22.113

8.  TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

Authors:  Keiichiro Honma; Shinobu Tsuzuki; Masao Nakagawa; Hiroyuki Tagawa; Shigeo Nakamura; Yasuo Morishima; Masao Seto
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

9.  Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.

Authors:  Aldo M Roccaro; Xavier Leleu; Antonio Sacco; Xiaoying Jia; Molly Melhem; Anne-Sophie Moreau; Hai T Ngo; Judith Runnels; Abdelkareem Azab; Feda Azab; Nicholas Burwick; Mena Farag; Steven P Treon; Michael A Palladino; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-03-03       Impact factor: 22.113

10.  Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells.

Authors:  Kasyapa S Chitta; A Nazmul H Khan; Noreen Ersing; Abhisek Swaika; Aisha Masood; Aneel Paulus; Abdul Qadeer; Pooja Advani; Taimur Sher; Kena C Miller; Kelvin Lee; Asher A Chanan-Khan
Journal:  Leuk Lymphoma       Date:  2013-07-01
View more
  28 in total

1.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

2.  Downregulation of ubiquitin-specific protease 14 (USP14) inhibits breast cancer cell proliferation and metastasis, but promotes apoptosis.

Authors:  Lianxin Zhu; Shuyun Yang; Song He; Fulin Qiang; Jing Cai; Rong Liu; Changjiang Gu; Zengya Guo; Chen Wang; Wei Zhang; Chunhui Zhang; Yingying Wang
Journal:  J Mol Histol       Date:  2015-12-28       Impact factor: 2.611

3.  EIF3m promotes the malignant phenotype of lung adenocarcinoma by the up-regulation of oncogene CAPRIN1.

Authors:  Xinwei Liu; Dulei Xiang; Chong Xu; Ruonan Chai
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

4.  Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.

Authors:  Ian D Ferguson; Yu-Hsiu T Lin; Christine Lam; Hao Shao; Kevin M Tharp; Martina Hale; Corynn Kasap; Margarette C Mariano; Audrey Kishishita; Bonell Patiño Escobar; Kamal Mandal; Veronica Steri; Donghui Wang; Paul Phojanakong; Sami T Tuomivaara; Byron Hann; Christoph Driessen; Brian Van Ness; Jason E Gestwicki; Arun P Wiita
Journal:  Cell Chem Biol       Date:  2022-07-18       Impact factor: 9.039

Review 5.  Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors.

Authors:  Shiyao Chen; Yunqi Liu; Huchen Zhou
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

6.  Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.

Authors:  A Paulus; S Akhtar; T R Caulfield; K Samuel; H Yousaf; Y Bashir; S M Paulus; D Tran; R Hudec; D Cogen; J Jiang; B Edenfield; A Novak; S M Ansell; T Witzig; P Martin; M Coleman; V Roy; S Ailawadhi; K Chitta; S Linder; A Chanan-Khan
Journal:  Blood Cancer J       Date:  2016-11-04       Impact factor: 11.037

7.  Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia.

Authors:  V S Tompkins; R Sompallae; T R Rosean; S Walsh; M Acevedo; A L Kovalchuk; S-S Han; X Jing; C Holman; J E Rehg; S Herms; J S Sunderland; H C Morse; S Janz
Journal:  Blood Cancer J       Date:  2016-11-04       Impact factor: 11.037

8.  The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5.

Authors:  You-Take Oh; Liang Deng; Jiusheng Deng; Shi-Yong Sun
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

Review 9.  Proteomics in Traditional Chinese Medicine with an Emphasis on Alzheimer's Disease.

Authors:  Yanuar Alan Sulistio; Klaus Heese
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-18       Impact factor: 2.629

10.  The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells.

Authors:  Andrea Tomasella; Raffaella Picco; Sonia Ciotti; Andrea Sgorbissa; Elisa Bianchi; Rossella Manfredini; Fabio Benedetti; Valentina Trimarco; Federica Frezzato; Livio Trentin; Gianpietro Semenzato; Domenico Delia; Claudio Brancolini
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.